Canal P, Villeneuve G, Bugat R, Armand J P, Soula G
Pathol Biol (Paris). 1984 Apr;32(4):245-50.
Serial measurements of lactate dehydrogenase (LDH) and of its isoenzymes have been assessed as an additional marker in a study of 44 patients with non seminomatous germ cell tumors of the testis. Its interest was compared with standard markers (AFP, beta HCG) related to clinical staging, histopathologic types and extent of the disease. Although LDH measurements were most frequently increased in stage III, its frequency of elevation was however lower than specific markers one. Abnormal levels of isoenzyme 1 could increased sensitivity of that determination. Indeed, LDH 1 was increased in all 15 cases for which it was determined, while total LDH was only disturbed in 8 cases. In patients with advanced testicular cancer and elevated LDH levels, sequential measurements of this parameter reflected the response to the therapy. A poor prognosis was associated with pathological level of LDH: while 92% of patients with normal level had a survival time upper than 5 years, no patient with elevated LDH had a survival time upper than 4 years; this difference was essentially significant in advanced stages. Serial measurement of LDH was of value as prognostic indicator and when elevated, it might be utilized as a guide for response to therapy.
在一项对44例睾丸非精原细胞瘤患者的研究中,乳酸脱氢酶(LDH)及其同工酶的系列测量已被评估为一种辅助标志物。将其与与临床分期、组织病理学类型和疾病范围相关的标准标志物(甲胎蛋白、β人绒毛膜促性腺激素)进行了比较。虽然LDH测量值在III期最常升高,但其升高频率低于特异性标志物。同工酶1的异常水平可提高该测定的敏感性。确实,在测定的所有15例病例中LDH 1均升高,而总LDH仅在8例中出现异常。在晚期睾丸癌且LDH水平升高的患者中,该参数的系列测量反映了对治疗的反应。预后不良与LDH的病理水平相关:LDH水平正常的患者中92%的生存时间超过5年,而LDH升高的患者中无生存时间超过4年的;这种差异在晚期尤为显著。LDH的系列测量作为预后指标有价值,当其升高时,可作为治疗反应的指导。